Brineura

Brineura Uses, Dosage, Side Effects, Food Interaction and all others data.

Brineura is an enzyme replacement treatment for a specific form of Batten disease. It was the first FDA-approved treatment to slow loss of walking ability (ambulation) in symptomatic pediatric patients 3 years of age and older with late infantile neuronal ceroid lipofuscinosis type 2 (CLN2), also known as tripeptidyl peptidase-1 (TPP1) deficiency. Intraventricular administration of the drug allows significant uptake into the brain. Brineura was approved in April, 2017 (as Brineura).

Brineura contains the active substance tripeptidyl peptidase-1 (rhTPP1), a recombinant human lysosomal exopeptidase which cleaves the N-terminal of tripeptides with a broad substrate specificity. Brineura slows the progressive decline in motor function caused by abnormal motor signalling in the brain by restoring the normal levels and activity of TPP1.

Trade Name Brineura
Generic Cerliponase alfa
Cerliponase alfa Other Names Cerliponase alfa, Immature cell growth-inhibiting gene 1 protein, Immature human tripeptidyl-peptidase 1, Immature lysosomal pepstatin-insensitive protease, Immature tripeptidyl-peptidase I
Weight 150mg/5ml,
Type Injectable kit
Weight 59.0 Da (glycosylated)
Groups Approved, Investigational
Therapeutic Class
Manufacturer
Available Country United States,
Last Updated: September 19, 2023 at 7:00 am
Brineura
Brineura

Uses

Brineura is an enzyme replacement therapy used to treat neuronal ceroid lipofuscinosis type 2 (CLN2) disease, also known as tripeptidyl peptidase 1 (TPP1) deficiency.

Brineura is a treatment for late infantile neuronal ceroid lipofuscinosis type 2 (CLN2) disease to decelerate the progressive motor function decline in patients 3 years of age and older. CLN2 disease is a form of Batten disease, a rare inherited neurodegenerative disorder and is associated with seizures, ataxia, rapid loss of language and motor functions, blindness, and early death . It is caused by the lack the lysosomal enzyme tripeptidyl peptidase-1 (TPP1) and subsequent accumulation of lysosomal storage materials normally metabolized by this enzyme in the central nervous system.

Brineura is also used to associated treatment for these conditions: Neuronal ceroid lipofuscinosis type 2

How Brineura works

The mature form of enzyme contains 5 consensus N-glycosylation sites with high mannose, phosphorylated high mannose and complex glycosylation structures. It is taken up by LINCL fibroblasts and translocated to the lysosomes through the Cation Independent Mannose-6-Phosphate Receptor (CI-MPR, also known as M6P/IGF2 receptor). Brineura is activated in the lysosome under low pH conditions and the activated proteolytic form of rhTPP1 cleaves tripeptides from the N-terminus of stored proteins.

Toxicity

No data from carcinogenicity, genotoxicity, and fertility studies. Unwanted effects of cerliponase alfa treatment include pyrexia, ECG abnormalities, decreased CSF protein, seizure and hypersensitivity.

Food Interaction

No interactions found.

Volume of Distribution

The estimated CSF volume of distribution of cerliponase alfa following intraventricular infusion of 300mg of Brineura (median Vss = 245 mL) exceeds the typical CSF volume (100 mL) .

Elimination Route

Refer to FDA Label

Half Life

Refer to FDA Label

Clearance

Refer to FDA Label

Innovators Monograph

You find simplified version here Brineura

*** Taking medicines without doctor's advice can cause long-term problems.
Share